Evidence map›Paper›PMID 25109853›Full record

ReviewAdvanced drug delivery reviews2014

3D tissue-engineered model of Ewing's sarcoma.

Salah-Eddine Lamhamedi-Cherradi, Marco Santoro, Vandhana Ramammoorthy, Brian A Menegaz, Geoffrey Bartholomeusz, Lakesla R Iles, Hesham M Amin, J Andrew Livingston, Antonios G Mikos, Joseph A Ludwig

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. 3D Ewing Sarcoma Modeling for Metabolic Studies.Methods in molecular biology (Clifton, N.J.) · 2027
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Journal of bone oncology · 2021
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Biomechanical forces in tissue engineered tumor models.Current opinion in biomedical engineering · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Salah-Eddine Lamhamedi-CherradiDepartment of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77054, USA.
Marco SantoroDepartment of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77054, USA; Department of Chemical and Biomolecular Engineering, Rice University, Houston, TX 77005, USA; Department of Bioengineering, Rice University, Houston, TX 77005, USA.
Vandhana RamammoorthyDepartment of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77054, USA.
Brian A MenegazDepartment of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77054, USA.
Geoffrey BartholomeuszDepartment of Experimental Therapeutic, SiRNA screen laboratory, (MDACC), Houston, TX 77005, USA.
Lakesla R IlesDepartment of Experimental Therapeutic, SiRNA screen laboratory, (MDACC), Houston, TX 77005, USA.
Hesham M AminDepartment of Hematopathology (MDACC), Houston, TX 77005, USA.
J Andrew LivingstonDivision of Cancer Medicine (MDACC), Houston, TX 77005, USA.
Antonios G MikosDepartment of Chemical and Biomolecular Engineering, Rice University, Houston, TX 77005, USA; Department of Bioengineering, Rice University, Houston, TX 77005, USA.
Joseph A LudwigDepartment of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77054, USA. Electronic address: jaludwig@mdanderson.org.

Funding

Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphomaR01CA151533 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMIN, HESHAM M · 2011 to 2015
$1.6M
NCI NIH HHS R01 CA151533
6 · The paper itself

Abstract

Despite longstanding reliance upon monolayer culture for studying cancer cells, and numerous advantages from both a practical and experimental standpoint, a growing body of evidence suggests that more complex three-dimensional (3D) models are necessary to properly mimic many of the critical hallmarks associated with the oncogenesis, maintenance and spread of Ewing's sarcoma (ES), the second most common pediatric bone tumor. And as clinicians increasingly turn to biologically-targeted therapies that exert their effects not only on the tumor cells themselves, but also on the surrounding extracellular matrix, it is especially important that preclinical models evolve in parallel to reliably measure antineoplastic effects and possible mechanisms of de novo and acquired drug resistance. Herein, we highlight a number of innovative methods used to fabricate biomimetic ES tumors, encompassing both the surrounding cellular milieu and the extracellular matrix (ECM), and suggest potential applications to advance our understanding of ES biology, preclinical drug testing, and personalized medicine.

Indexed as

Tissue EngineeringAnimalsAntineoplastic AgentsBone NeoplasmsChildDrug Evaluation, PreclinicalDrug Resistance, NeoplasmExtracellular MatrixHumansModels, BiologicalPrecision MedicineSarcoma, EwingAntineoplastic Agents3DECMEwing's sarcomaMCTSPreclinical testingScaffoldsTissue-engineeringTumor model

Identifiers

PMID25109853
PMCPMC4397982

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.